Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01VGQ
|
|||
| Drug Name |
MG-1101
|
|||
| Synonyms |
MBR-193.02; MBRI-93.02; PTH (osteoporosis), Green Cross/BDD/CCDRD; parathyroid gland-secreted peptide (osteoporosis), Green Cross; parathyroid hormone, Green Cross/BDD/CCDRD
Click to Show/Hide
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Parathyroid hormone (PTH) | Target Info | Modulator | [1] |
| Reactome | Class B/2 (Secretin family receptors) | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Endochondral Ossification | |||
| Osteoblast Signaling | ||||
| Vitamin D Receptor Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.J Bone Miner Res.2012 Aug;27(8):1811-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.